Skip to main content
. Author manuscript; available in PMC: 2020 Jun 1.
Published in final edited form as: Am J Transplant. 2018 Dec 15;19(6):1671–1683. doi: 10.1111/ajt.15175

Figure 6.

Figure 6.

Longitudinal Assessment of Donor-Specific Antibody the First 5 Years Post Transplant in Eculizumab-Treated Patients. The line plots shows results from baseline to 5 years in subsets of patients with testing: A, BFXM; B, Sum MFI anti-HLA class I and II; C, Sum MFI anti-HLA class I; D, Sum MFI anti-HLA class II. BFXM was expressed as mean channel shift (≥106 was considered positive). Matched-pairs analysis was performed to compare results from baseline to 5 years. BFXM indicates B-cell flow cytometric crossmatch; HLA, human leukocyte antigen; MFI, mean fluorescence intensity.